Research comparison
Retatrutide vs. tirzepatide
Both are lipidated incretin analogues with a fatty-acid side chain for albumin binding. Tirzepatide activates two receptors (GIP and GLP-1), retatrutide additionally the glucagon receptor. Tirzepatide is an approved drug substance; retatrutide is in clinical development.
| Property | Retatrutid | Tirzepatid |
|---|---|---|
| Profile | Lipidated peptide and triple agonist at the GIP, GLP-1 and glucagon receptors, in clinical development (investigational code LY3437943). | Dual agonist at the GIP and GLP-1 receptors with a fatty-acid side chain; approved as a medicinal substance. |
| Sequence | – | – |
| Length | – | – |
| Formula | – | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molar mass | – | 4,813 g/mol |
| CAS | – | 2023788-19-2 |
| Purity (current batch, HPLC) | 99.72 % | – |
| Price per mg from | €3.33 | €5.40 |
In the range
For research and laboratory use only. Not for use in humans or animals. The data summarises literature and lab reports; it is not a recommendation for use.